Windtree Therapeutics (Windtree Therapeutics) Total Long-Term Liabilities : $25.02 Mil (As of Dec. 2023)

View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Windtree Therapeutics's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was $25.02 Mil.

Windtree Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Windtree Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windtree Therapeutics Total Long-Term Liabilities Chart

Windtree Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

36.22

37.20

27.99

25.49

25.02

Windtree Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Long-Term Liabilities	Get a 7-Day Free Trial															25.49	25.39	25.18	24.86	25.02

Windtree Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Windtree Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Windtree Therapeutics (Windtree Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622

Website

https://www.windtreetx.com

Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug-delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.

Executives

Craig Fraser	director, officer: Chief Executive Officer	AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew	officer: VP, Controller, & CAO	WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck	director	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill	officer: SVP & CFO	4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc.	10 percent owner	7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc.	10 percent owner	7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman	officer: SVP & General Counsel	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis	officer: SVP & COO	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson	officer: SVP, Chief Development Officer	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh	director	75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott	director
Joseph M Mahady	director	16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber	director	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976